Living Cell Technologies Limited (LVCLF)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 125.2 Thousand AUD | 201.99% |
| 2023 | 41.45 Thousand AUD | 1457.44% |
| 2022 | 2662.00 AUD | -98.78% |
| 2021 | 218.87 Thousand AUD | 6808.78% |
| 2020 | 3168.00 AUD | -67.57% |
| 2019 | 9769.00 AUD | -91.95% |
| 2018 | 121.4 Thousand AUD | 5.31% |
| 2017 | 115.27 Thousand AUD | 1040.92% |
| 2016 | 10.1 Thousand AUD | -66.74% |
| 2015 | 30.38 Thousand AUD | -95.09% |
| 2014 | 618.64 Thousand AUD | 20.59% |
| 2013 | 513 Thousand AUD | 80.0% |
| 2012 | 285 Thousand AUD | 61.44% |
| 2011 | 176.53 Thousand AUD | -65.86% |
| 2010 | 517.08 Thousand AUD | 177.31% |
| 2009 | 186.46 Thousand AUD | 258.96% |
| 2008 | 51.94 Thousand AUD | 183.98% |
| 2007 | 18.29 Thousand AUD | 1299.54% |
| 2006 | 1307.00 AUD | -98.0% |
| 2005 | 65.41 Thousand AUD | -10.04% |
| 2004 | 72.71 Thousand AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 FY | - AUD | -100.0% |
| 2024 Q2 | - AUD | 0.0% |
| 2024 Q3 | 62.6 Thousand AUD | 0.0% |
| 2024 Q4 | 62.6 Thousand AUD | 0.0% |
| 2024 Q1 | - AUD | -100.0% |
| 2023 Q1 | - AUD | -100.0% |
| 2023 Q3 | 21 Thousand AUD | 0.0% |
| 2023 Q4 | 21 Thousand AUD | 0.0% |
| 2023 Q2 | - AUD | 0.0% |
| 2023 FY | 41.45 Thousand AUD | 1457.44% |
| 2022 Q1 | - AUD | 100.0% |
| 2022 FY | 2662.00 AUD | -98.78% |
| 2022 Q2 | - AUD | 0.0% |
| 2022 Q4 | 960.00 AUD | -43.63% |
| 2022 Q3 | 1703.00 AUD | 0.0% |
| 2021 FY | 218.87 Thousand AUD | 6808.78% |
| 2021 Q2 | -283.76 Thousand AUD | 0.0% |
| 2021 Q1 | -283.76 Thousand AUD | 37.52% |
| 2021 Q3 | -262.48 Thousand AUD | 7.5% |
| 2021 Q4 | -262.48 Thousand AUD | 0.0% |
| 2020 FY | 3168.00 AUD | -67.57% |
| 2020 Q3 | -454.13 Thousand AUD | 25.7% |
| 2020 Q2 | -611.21 Thousand AUD | -22.78% |
| 2020 Q4 | -454.13 Thousand AUD | 0.0% |
| 2020 Q1 | -497.79 Thousand AUD | -309.64% |
| 2019 FY | 9769.00 AUD | -91.95% |
| 2019 Q1 | 147.38 Thousand AUD | -23.14% |
| 2019 Q4 | 237.45 Thousand AUD | 0.0% |
| 2019 Q2 | 147.38 Thousand AUD | -0.0% |
| 2019 Q3 | 237.45 Thousand AUD | 61.11% |
| 2018 Q1 | 191.84 Thousand AUD | -42.12% |
| 2018 FY | 121.4 Thousand AUD | 5.31% |
| 2018 Q4 | 191.76 Thousand AUD | 0.0% |
| 2018 Q3 | 191.76 Thousand AUD | -0.04% |
| 2018 Q2 | 191.84 Thousand AUD | 0.0% |
| 2017 Q3 | 331.42 Thousand AUD | 31.58% |
| 2017 FY | 115.27 Thousand AUD | 1040.92% |
| 2017 Q4 | 331.42 Thousand AUD | 0.0% |
| 2017 Q1 | 251.88 Thousand AUD | -10.97% |
| 2017 Q2 | 251.88 Thousand AUD | 0.0% |
| 2016 Q2 | 137.8 Thousand AUD | -0.0% |
| 2016 FY | 10.1 Thousand AUD | -66.74% |
| 2016 Q4 | 282.91 Thousand AUD | 0.0% |
| 2016 Q3 | 282.91 Thousand AUD | 105.3% |
| 2016 Q1 | 137.8 Thousand AUD | 275.53% |
| 2015 Q4 | 36.69 Thousand AUD | 0.0% |
| 2015 FY | 30.38 Thousand AUD | -95.09% |
| 2015 Q2 | 92.99 Thousand AUD | 0.0% |
| 2015 Q3 | 36.69 Thousand AUD | -60.54% |
| 2015 Q1 | 92.99 Thousand AUD | -63.21% |
| 2014 Q3 | 252.78 Thousand AUD | 13.91% |
| 2014 Q2 | 221.91 Thousand AUD | 0.0% |
| 2014 Q1 | 221.91 Thousand AUD | -1.34% |
| 2014 FY | 618.64 Thousand AUD | 20.59% |
| 2014 Q4 | 252.78 Thousand AUD | 0.0% |
| 2013 Q3 | 224.92 Thousand AUD | 0.0% |
| 2013 FY | 513 Thousand AUD | 80.0% |
| 2013 Q4 | 224.92 Thousand AUD | 0.0% |
| 2012 FY | 285 Thousand AUD | 61.44% |
| 2011 FY | 176.53 Thousand AUD | -65.86% |
| 2010 FY | 517.08 Thousand AUD | 177.31% |
| 2009 FY | 186.46 Thousand AUD | 258.96% |
| 2008 FY | 51.94 Thousand AUD | 183.98% |
| 2007 FY | 18.29 Thousand AUD | 1299.54% |
| 2006 FY | 1307.00 AUD | -98.0% |
| 2005 FY | 65.41 Thousand AUD | -10.04% |
| 2004 FY | 72.71 Thousand AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | 1611.165% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 99.165% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 98.722% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -90.482% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 98.93% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.895% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 466.618% |
| Marizyme, Inc. | 457.7 Thousand USD | 72.646% |
| Genus plc | 178.7 Million USD | 99.93% |
| Pharming Group N.V. | 220.1 Million USD | 99.943% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -101.202% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | 69.476% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1238.182% |
| ContraFect Corporation | -154 Thousand USD | 181.299% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -63.104% |
| IMV Inc. | -962.29 Thousand USD | 113.011% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 132.31% |
| ONE Bio Corp. | 20.12 Million USD | 99.378% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 99.689% |
| Mesoblast Limited | -35.16 Million USD | 100.356% |
| MultiCell Technologies, Inc. | 49.32 USD | -253752.393% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 99.557% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.969% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -3936.106% |
| Biomind Labs Inc. | -15.42 Thousand USD | 911.722% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 110.967% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -78.857% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 200.764% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 2628.271% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 350.4% |
| Arch Therapeutics, Inc. | -2439.00 USD | 5233.251% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | 10.89% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -156.033% |
| Q BioMed Inc. | -8988.00 USD | 1492.968% |
| GB Sciences, Inc. | -624.00 USD | 20164.103% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 245.534% |
| CSL Limited | 7.56 Billion USD | 99.998% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.718% |
| Enzolytics Inc. | 30.7 Thousand USD | -307.711% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 74.048% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 228.391% |
| argenx SE | 1.1 Billion USD | 99.989% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 100.485% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 60292.308% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 124.334% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 1513.731% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 79.721% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 249.316% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 87.328% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 98.697% |
| Kadimastem Ltd | -630.13 Thousand USD | 119.869% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | 99.188% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1157.879% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 359.433% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 29.089% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | 29.089% |
| Affymax, Inc. | 1.35 Million USD | 90.775% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 97.283% |
| CytoDyn Inc. | -29 Thousand USD | 531.724% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 72.18% |
| SYBLEU INC | 11.69 Thousand USD | -970.451% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 139.185% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 133.566% |
| Neutra Corp. | 14.33 Thousand USD | -773.387% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 252.683% |
| PureTech Health plc | -1.6 Million USD | 107.81% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 112.505% |
| IXICO plc | 3.27 Million USD | 96.171% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 118.04% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 106.991% |
| CSL Limited | 7.7 Billion USD | 99.998% |
| Cellectis S.A. | 18 Thousand USD | -595.556% |